Clinical management of selected oral fungal and viral infections during HIV-disease.
The purpose of this review is to describe current possibilities of management of selected fungal and viral oral opportunistic infections including oral candidiasis, herpes simplex type 1 and 2-related lesions (HSV1,2), oral hairy leukoplakia (OHL) and oral lesions associated with human papilloma viruses (HPV). Less common diseases such as cytomegalovirus infection or human herpes virus type 8 associated with Kaposi's sarcoma and others are not considered. In a number of instances lifelong therapy or prophylaxis has to be instituted. Antiretroviral combination therapy, also called highly active antiretroviral therapy (HAART), has considerably changed the frequency of oral lesions caused by opportunistic agents. A short description of the antiretroviral agents available including respective side-effects is presented.
Reichart
P A
PA
Abteilung für Oralchirurgie und Zahnärztliche Röntgenologie, Universitätsklinikum Charité, Medizinische Fakultät, Humboldt-Universität zu Berlin, Germany.
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D019380:Anti-HIV Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D002180:Candidiasis, Oral / Q000188:drug therapy; D004266:DNA Virus Infections / Q000188:drug therapy*; D015658:HIV Infections; D018259:Herpesvirus 1, Human; D018258:Herpesvirus 2, Human; D006801:Humans; D017733:Leukoplakia, Hairy / Q000188:drug therapy; D009059:Mouth Diseases / Q000188:drug therapy / Q000382:microbiology* / Q000821:virology; D009181:Mycoses / Q000188:drug therapy*; D027383:Papillomaviridae; D030361:Papillomavirus Infections / Q000188:drug therapy; D013283:Stomatitis, Herpetic / Q000188:drug therapy
D019380:Anti-HIV Agents; D000998:Antiviral Agents